The COVID-19 has been prevalent in many parts of the country and though its intensity has decreased for the last one month, there is the threat of the second wave emergence. This is evident from the various parts of the world and India into exemption to it, as the scientists claim. So, the immediate release of COVID vaccine seems to be the only life line for the people who are much prone to the serious effects of the disease.
The Indians rested all their hopes on the COVAXIN which is being developed by the Bharat Bio-tech India private Limited. Going into detail, Haryana Home Minister Anil Vij said that the third phase of clinical trials of Covaxin, developed by Bharat Biotech International Limited. It is known that the phase-3 trials are the most crucial and probably the final step before the release of the vaccine into the market.
Bharat Biotech is conducting the largest clinical trial in the country. Bharat Biotech said that the clinical trials will be conducted across 22 sites in India. The trials will be conducted on 26,000 volunteers. Coming to the progress across the globe in vaccine development, two pharmaceutical corporations Pfizer and Moderna announced that their vaccines have achieved more than 90 percent efficiency.
